MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

819.54 2.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

796.13

Max

819.54

Belangrijke statistieken

By Trading Economics

Inkomsten

7.8B

8.8B

Verkoop

2.1B

14B

K/W

Sectorgemiddelde

70.41

63.778

EPS

5.32

Dividendrendement

0.73

Winstmarge

65.172

Werknemers

47,000

EBITDA

1.2B

6.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.58% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.73%

2.39%

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-43B

742B

Vorige openingsprijs

817.44

Vorige sluitingsprijs

819.54

Nieuwssentiment

By Acuity

40%

60%

146 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 apr 2025, 23:15 UTC

Belangrijke Marktbewegers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2 apr 2025, 16:53 UTC

Top Nieuws

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 apr 2025, 22:31 UTC

Top Nieuws

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 apr 2025, 21:47 UTC

Top Nieuws

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 mrt 2025, 15:54 UTC

Top Nieuws

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 15:14 UTC

Top Nieuws

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 feb 2025, 14:30 UTC

Top Nieuws

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 feb 2025, 12:00 UTC

Top Nieuws

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Top Nieuws
Winsten

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Winsten

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 feb 2025, 14:32 UTC

Marktinformatie
Winsten

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 feb 2025, 13:18 UTC

Top Nieuws
Winsten

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6 feb 2025, 12:24 UTC

Winsten

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6 feb 2025, 12:01 UTC

Winsten

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6 feb 2025, 11:49 UTC

Winsten

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6 feb 2025, 11:48 UTC

Winsten

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6 feb 2025, 11:47 UTC

Winsten

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6 feb 2025, 11:46 UTC

Winsten

Eli Lilly 4Q Gross Margin 82.2% >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly Sees FY Rev $58B-$61B >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q Net $4.41B >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q EPS $4.88 >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6 feb 2025, 11:45 UTC

Winsten

Eli Lilly 4Q Rev $13.53B >LLY

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

27.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,043.87 USD  27.58%

Hoogste 1,190 USD

Laagste 900 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Technische score

By Trading Central

797 / 825.32Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

146 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.